Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss in Androgenetic alopecia (AGA) is due to altered cell sensitivity to hormones, not increased hormone levels. Hair growth periods shorten over time, causing hair to become thinner and shorter. This is linked to miscommunication between cell pathways in hair follicles. There's also a change in gene expression related to blood vessels and cell growth in balding hair follicles. The exact molecular causes of AGA are still unclear.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

New markers and pathways have been found in skin tumors, helping better understand and diagnose them.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

Particulate matter causes inflammation in hair cells, potentially harming hair growth.

Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.

Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.

New insights into cell communication in psoriasis suggest innovative drug treatments.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

Key genes linked to hair growth and cancer were identified in hairless mice.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Regenerative therapies show promise for treating vitiligo and alopecia areata.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

NF-κB is crucial for zebrafish heart repair, affecting heart cell growth and repair processes.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Stress-related hair loss was reversed with a special medication.

Tofacitinib may effectively regrow hair in alopecia totalis patients.